Ultime notizie per Nicola Mining Inc (OTC:HUSID) Azioni

Nicola Mining Inc

Baird analyst Joe Vruwink maintains Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) with a Outperform and raises the price target from $305 to $330.

News

Price Target

Analyst Ratings

ADSK

Baird Maintains Outperform on Autodesk, Raises Price Target to $330

ARWR

Arrowhead Pharmaceuticals Submits New Drug Application To The US FDA For Plozasiran In Treatment Of Familial Chylomicronemia Syndrome

Loop Capital analyst Gary Mobley upgrades Monolithic Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>) from Hold to Buy and maintains the price target from $660 to $660.

Upgrades

MPWR

Loop Capital Upgrades Monolithic Power Systems to Buy, Maintains Price Target to $660

WIIM

TWST

Twist Bioscience shares are trading higher after the company reported better-than-expected Q4 EPS and sales.

CVS Health shares are trading higher after the company announced the addition of four new directors to its board.

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Kura Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>) with a Buy and maintains $32 price target.

Reiteration

KURA

HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $32 Price Target

BIIB

Biogen shares are trading lower after Needham downgraded the stock from Buy to Hold.

MARA

Marathon Digital Holdings shares are trading lower after the company announced a $700 million convertible note offering to boost Bitcoin holdings and repurchase debt.

On November 13, 2024, Syros Pharmaceuticals, Inc. (the "Company") gave notice to QIAGEN Manchester Limited ("QIAGEN") of its election to terminate the Master Collaboration Agreement dated March 7, 2022 (the "Agreement") relating to the development and commercialization of an assay as a companion diagnostic test for use with tamibarotene as a result of the failure of the Company's SELECT-MDS-1 Phase3 trial evaluating tamibarotene to meet its primary endpoint of complete response rate, which was previously disclosed on the Company's Current Report on Form 8-Kfiled with the U.S. Securities and Exchange Commission (the "SEC") on November 13, 2024. The termination will be effective 90 days following such notice.

QGEN

SYRS

Syros Pharmaceuticals Gave Notice To Qiagen Manchester Limited Of Its Election To Terminate The Master Collaboration Agreement Dated March 7, 2022

Baird analyst Joel Beatty maintains Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Outperform and raises the price target from $154 to $162.

JAZZ

Baird Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $162

Warner Bros. Discovery shares are trading higher after a WSJ report indicating that the company resolved a TV rights legal dispute with the NBA.

HC Wainwright &amp; Co. analyst Ed Arce reiterates Akero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKRO#NASDAQ">AKRO</a>) with a Buy and maintains $50 price target.

AKRO

HC Wainwright & Co. Reiterates Buy on Akero Therapeutics, Maintains $50 Price Target

Barclays analyst Nicholas Campanella downgrades Pinnacle West Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNW#NYSE">PNW</a>) from Overweight to Equal-Weight and lowers the price target from $93 to $91.

Downgrades

Barclays Downgrades Pinnacle West Capital to Equal-Weight, Lowers Price Target to $91

Zimmer Biomet Receives CE Mark Certification For The Persona Revision Knee System

Baird analyst David George maintains Comerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>) with a Outperform and raises the price target from $75 to $80.

Baird Maintains Outperform on Comerica, Raises Price Target to $80

TSLA

Tesla shares are trading higher following reports of President-elect Donald Trump's policy outlook on regulations for autonomous driving.

Baird analyst Vikram Kesavabhotla upgrades Roku (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) from Neutral to Outperform and raises the price target from $70 to $90.

ROKU

Baird Upgrades Roku to Outperform, Raises Price Target to $90

RGNX: 30% &#x7C; <a href="https://www.benzinga.com//node/42033259">REGENXBIO shares are trading higher after the company announced dosing the first patient in its pivotal trial for Duchenne gene therapy.</a>
&nbsp;
NIVF: 123% &#x7C; <a href="https://www.benzinga.com//node/42033041">NewGenIvf Inks Binding Term Sheet With California-Based Institutional Investor White Lion Capital, LLC, For $100M Equity Line Of Credit, Expandable To $500M</a>
&nbsp;
ALDX: 10% &#x7C; <a href="https://www.benzinga.com//node/42033306">Aldeyra Therapeutics shares are trading higher after the FDA accepted its resubmitted new drug application for Reproxalap for the treatment of dry eye disease, prompting the company to announce an expansion of its option agreement with AbbVie.</a>

Movers

Trading Ideas

ALDX

NIVF

RGNX

Market-Moving News for November 18th

Binance CEO Richard Teng on Monday expressed strong optimism for the future of the cryptocurrency industry, predicting that 2025 will surpass the <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41984505/bitcoin-to-peak-at-180000-says-vanecks-head-of-digital-assets-research">growth and adoption seen in 2024</a>.
Teng's comments come amid growing institutional interest and regulatory clarity, which he believes are setting the stage for <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42027183/michael-saylor-predicts-bitcoin-boom-says-100k-on-the-horizon">a transformative year for digital assets.</a>
What Happened: &#8220;2024 has been a good year, but I firmly believe 2025 will be even better,&#8221; Teng told Benzinga in an interview.
Highlighting Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) performance and the factors driving market growth, he pointed to the approval of <a href="https://www.benzinga.com/money/best-spot-bitcoin-etfs">Bitcoin ETFs</a> as a significant catalyst.
&#8220;Earlier this year, we saw Bitcoin ETFs approved in the U.S. and globally, from Brazil to Hong Kong and Australia. The net inflow into Bitcoin ETFs has already surpassed that of gold ETFs within a year, demonstrating the immense pent-up demand,&#8221; Teng added.
Teng emphasized Bitcoin&#8217;s continued ascent as more <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42010782/goldman-sachs-expands-bitcoin-etf-holdings-to-710-million">institutions and governments embrace the asset. </a>
&#8220;This year, we've seen a significant uptick in institutional interest, with sovereign wealth funds and pension funds beginning to allocate Bitcoin reserves. This is a major positive for the industry as we move into 2025,&#8221; he said. 
He also noted that macroeconomic factors like controlled inflation and reduced interest rates globally will further bolster Bitcoin&#8217;s growth.
Addressing the role of <a href="https://www.benzinga.com/money/top-meme-coins">meme coins</a> in the burgeoning crypto industry , Teng acknowledged their appeal to new retail investors entering the market.
&#8220;Meme coins account for about 12% of trading volume, which is quite significant,&#8221; Teng noted. 
He described them as a gateway for beginners, saying, &#8220;Meme coins are fun, exciting, and relatable to young adults. They're often the first step into crypto for many novice investors.&#8221;
Responding to allegations of Binance <a href="https://x.com/LeonidasNFT/status/1855873702597943569">allegedly</a> listing pump-and-dump meme coin schemes, he said the crypto exchange followed stringent listing criteria, ensuring only projects with strong fundamentals make it onto their platform.
&#8220;If you look at some of these projects, they're not just about where they are today but where they aim to go in the future,&#8221; he said.
Teng attributed the industry's growth to increasing institutional involvement and regulatory clarity. 
&#8220;Close to one-third of global regulators now have frameworks for crypto. This clarity is critical for mass adoption,&#8221; he explained.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42016508/dogecoin-to-1-until-december-probably-not-happening-polymarket-traders-say">Dogecoin To $1 By December? Probably Not Happening, Polymarket Traders Say</a>
He added that 2024 witnessed a doubling of institutional onboarding at Binance compared to the previous year, with the trend expected to continue into 2025.
&#8220;Institutions spend months conducting due diligence before entering this space. Now that the U.S. and global environments are more favorable, we expect even more institutions to onboard in 2025,&#8221; Teng said.
Teng stressed the importance of working with governments to develop smart regulatory frameworks that balance innovation with risk management. 
&#8220;We are the most licensed and regulated crypto exchange globally, with 20 licenses across the world, including in India and Argentina,&#8221; Teng stated. 
He believes that a collaborative approach with regulators can unlock the full potential of blockchain and digital assets, making them foundational technologies for global economic growth.
&#8220;Crypto has changed the lives of so many people, especially where banking systems are expensive or inaccessible,&#8221; he said. 
He added that blockchain's transparency and efficiency are reshaping industries from supply chain management to real estate.
He also emphasized the importance of regulatory clarity for the growth of the cryptocurrency industry. 
Teng highlighted the challenges posed by the SEC&#8217;s enforcement-led approach in recent years, which <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41993524/gary-gensler-hints-at-ending-his-stint-as-sec-chair-defends-crypto-regulation-agenda">created uncertainty and hindered innovation. </a>
&#8220;Regulatory frameworks must strike a balance between managing risks and supporting innovation,&#8221; he said, adding that pro-crypto regulators who understand the transformative potential of blockchain technology can foster an environment conducive to mass adoption.
What&#8217;s Next: Teng's insights come as the crypto industry prepares for significant events, including Benzinga's <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> conference on Nov. 19.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42011875/solana-ripple-litecoin-etfs-may-be-on-the-table-under-trump-administration-industry-experts-think">Solana, Ripple, Litecoin ETFs May Be On The Table Under Trump Administration, Industry Experts Say</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$BTC

EXCLUSIVE: Binance CEO Richard Teng Says 2025 Will Outshine 2024 For Crypto

Baird analyst Joel Beatty upgrades Amylyx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) from Neutral to Outperform and raises the price target from $3 to $11.

Amplify YieldShares Oil Hedged MLP Income ETF

Comments

Nicola Mining Inc

Notizie

Ultime notizie per Nicola Mining Inc (OTC:HUSID) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO